MarketCap
Facebook
X
Telegram
AcelRx Pharmaceuticals Revenue | ACRX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 K | - | 651 K | 1.77 M | 2.82 M | 5.42 M | 2.29 M | 2.15 M | 8 M | 17.4 M | 19.3 M | 5.22 M | 29.5 M | 2.39 M | 1.07 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.5 M | 28 K | 6.99 M |
Quarterly Revenue AcelRx Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1 K | - | 27 K | - | - | - | - | - | 117 K | 253 K | - | - | 507 K | 570 K | 442 K | - | 1.86 M | 443 K | 511 K | - | 1.37 M | 2.92 M | 386 K | 475 K | 608 K | 941 K | 265 K | 613 K | 377 K | 818 K | 343 K | 740 K | 1.49 M | 2.66 M | 3.11 M | 6.44 M | 3.37 M | 4.53 M | 3.02 M | 1.73 M | 15.4 M | 1.92 M | 181 K | 226 K | 4.82 M | 71 K | 95 K | 27.6 M | 548 K | 407 K | 940 K | 1.68 M | 166 K | 224 K | 329 K | 624 K | 408 K | 40 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.6 M | 1 K | 2.01 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M |  USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 7.65 | 2.0 % | $ 114 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cronos Group
CRON
|
147 M | $ 3.31 | 2.8 % | $ 1.27 B | Canada |
 |
Harrow Health
HROW
|
272 M | $ 40.95 | 1.01 % | $ 1.51 B | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
297 M | $ 8.39 | 0.48 % | $ 541 M | USA |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
119 M | - | - | $ 150 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
78.2 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
19.5 M | $ 1.34 | 1.12 % | $ 2.26 M | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.64 | 2.33 % | $ 38.7 M | USA |
 |
cbdMD
YCBD
|
19.2 M | $ 0.51 | 0.43 % | $ 2.05 M | USA |
 |
Bausch Health Companies
BHC
|
10.3 B | $ 6.44 | 0.22 % | $ 2.39 B | Canada |
 |
Emergent BioSolutions
EBS
|
743 M | $ 5.08 | 5.39 % | $ 272 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.98 | 0.93 % | $ 4.21 M |  China |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.25 | 4.17 % | $ 119 M | Canada |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 14.25 | 3.98 % | $ 1.97 B | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 8.1 | 6.02 % | $ 291 M | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 5.1 | 0.57 % | $ 255 M | USA |
 |
Solid Biosciences
SLDB
|
8.09 M | $ 9.3 | 2.2 % | $ 814 M | USA |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.06 | 0.48 % | $ 23.8 M | USA |
 |
Canopy Growth Corporation
CGC
|
285 M | $ 1.05 | 1.43 % | $ 313 M | Canada |
 |
ProPhase Labs
PRPH
|
4.34 M | - | - | $ 5.07 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.94 | 3.41 % | $ 216 M | Canada |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.63 | 0.65 % | $ 183 M | USA |
 |
Organogenesis Holdings
ORGO
|
564 M | $ 1.8 | 0.27 % | $ 228 M | USA |
 |
Pacira BioSciences
PCRX
|
726 M | $ 24.67 | 3.52 % | $ 1.1 B | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.37 | 3.01 % | $ 354 M | Canada |
 |
Tilray
TLRY
|
821 M | $ 4.84 | 3.64 % | $ 4.31 B | Canada |